Sustained drug release and improved bioavailability of Ramizol®
PERTH, WESTERN AUSTRALIA, AUSTRALIA, April 9, 2018 /EINPresswire.com/ -- A scientific paper has been published in the journal Drug Development and Industrial Pharmacy that shows improved sustained drug release and improved bioavailability of the antibiotic Ramizol®, developed by Boulos & Cooper Pharmaceuticals.
The paper, entitled ‘Ramizol® Encapsulation into Extended Release PLGA Micro and Nanoparticle Systems for Subcutaneous and Intramuscular Administration: In Vitro and In Vivo Evaluation’, investigated the development of poly-lactic-(co-glycolic) acid particles to overcome the limitation of rapid plasma clearing when administered intravenously, and lack of bioavailability of the drug when administered orally.
Pharmacokinetic studies in Sprague Dawley rats confirmed extended absorption and enhanced bioavailability following subcutaneous and intramuscular dosing, with up to an 8-fold increase in Tmax and T1/2 when compared to the oral and intravenous routes.
Chief Executive Officer of Boulos & Cooper Pharmaceuticals, Dr Ramiz Boulos, said “These results show improved bioavailability and reduced drug clearing rate, allowing for less frequent dosing.” Dr Boulos said “These improvements will help us to use Ramizol® to target systemic infections.”
The research was undertaken jointly by the Australian company Boulos & Cooper Pharmaceuticals, the University of South Australia and Flinders University.
Download the paper here:
https://www.tandfonline.com/doi/abs/10.1080/03639045.2018.1459676
The paper, entitled ‘Ramizol® Encapsulation into Extended Release PLGA Micro and Nanoparticle Systems for Subcutaneous and Intramuscular Administration: In Vitro and In Vivo Evaluation’, investigated the development of poly-lactic-(co-glycolic) acid particles to overcome the limitation of rapid plasma clearing when administered intravenously, and lack of bioavailability of the drug when administered orally.
Pharmacokinetic studies in Sprague Dawley rats confirmed extended absorption and enhanced bioavailability following subcutaneous and intramuscular dosing, with up to an 8-fold increase in Tmax and T1/2 when compared to the oral and intravenous routes.
Chief Executive Officer of Boulos & Cooper Pharmaceuticals, Dr Ramiz Boulos, said “These results show improved bioavailability and reduced drug clearing rate, allowing for less frequent dosing.” Dr Boulos said “These improvements will help us to use Ramizol® to target systemic infections.”
The research was undertaken jointly by the Australian company Boulos & Cooper Pharmaceuticals, the University of South Australia and Flinders University.
Download the paper here:
https://www.tandfonline.com/doi/abs/10.1080/03639045.2018.1459676
Ramiz Boulos
Boulos & Cooper Pharmaceuticals Pty Ltd
+61431150538
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.